Prokineticin 2/Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma.

(1)

HAL Id: inserm-00261475

https://www.hal.inserm.fr/inserm-00261475

Submitted on 10 Nov 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Justin Monnier, Claire Piquet-Pellorce, Jean-Jacques Feige, Orlando Musso,

Bruno Clément, Bruno Turlin, Nathalie Théret, Michel Samson

To cite this version:

Justin Monnier, Claire Piquet-Pellorce, Jean-Jacques Feige, Orlando Musso, Bruno Clément, et al.. Prokineticin 2/Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma.. World Journal of Gastroenterology, Baishideng Publishing Group Co. Limited, 2008, 14 (8), pp.1182-91. �inserm-00261475�

(2)

V

E

G

F

/

1

8 S

D

NL NT HCC 0 0.4 0.8 1.2 1.6 2.0

v

W

F

/

1

8 S

C

0 1 2 3 4 5 6 7 NL NT HCC

B

E

F

G

V

E

G

F

/

1

8 S

P

K

2 -B

v

8 /

1

8 S

NL F1-3 F4 0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 PK2/Bv8 (150bp) PK1/EG-VEGF (81bp) β-Actin (250bp) NL n =4 HCC n =7 NT n =7 THP1

A

MW

P

K

2 -B

v

8 /

1

8 S

0 0.4 0.8 1.2 1.6 NL NT HCC p<0.05 p<0.01 p<0.01 p<0.01 p<0.01 NL F1-3 F4

v

W

F

/

1

8 S

0 0.5 1 1.5 2 2.5 3 3.5 4 p<0.01 p<0.01 p<0.01 NL F1-3 F4 0 0.2 0.4 0.6 0.8 1 1.2 1.4 p<0.01 p<0.05

(3)

CD31

CD34

VEGF

PK2/Bv8

Mouse IgG1

Rabbit IgG

PK2/Bv8

+ blocking peptide

(4)

NL NT HCC

C

D

6

8 /

1

8 S

B

0 0.5 1 1.5 2 2.5 3

*

A

CD68 PK2/Bv8 PK2/Bv8 + blocking Peptide

(5)

B

FSC-H S S C -H CD14-FITC C e ll N u m b e r 0 10 20 30 40 50 60 70 PK2/Bv8 PK1/EG-VEGF NL KC-Enr CD14+KC HSC HA 15% of KC-Enr

C

KC

E x p re s s io n r e la ti v e t o N L p<0.01 p<0.01

(6)

DAPI CD68-FITC PK2/Bv8-TRITC Merge

(7)

BC 1 HE PG 2 HE P3B B16 A2 NL CD14+ KC HSC HA E x p re s s io n r e la ti v e t o N L 0 10 20 30 40 50 60 PKR1 PKR2 p<0.05